Context This post follows Korea Quality Re-Rating Watch 2026-06-10, Korea liquidity is high but breadth is broken, Why KOSDAQ fell despite foreign buying, the Real Money flow framework, the foreign-investor KOSPI 168 / KOSDAQ 355 playbook, and the Samsung-Hynix-Micron parity follow-up. The previous notes focused on Samsung Electronics, SK Hynix, AI infrastructure concentration, and narrow foreign/institutional flows. This one isolates quality names worth revisiting in Q3 while the Samsung-Hynix concentration continues.
TL;DR
The Korean market is still organized around Samsung Electronics and SK Hynix. AI memory, HBM, foreign-investor playbooks, large-cap liquidity, and index contribution all keep pulling investors back to the same first question: can Samsung Electronics and SK Hynix be bought again?
But a second portfolio question matters:
While the Samsung-Hynix concentration continues, which quality stocks have improving numbers but have not yet been rewarded by price?
A mechanical local screen produces 35 companies. The filters are: FY2026 EPS consensus revised up by at least 5%, positive Q1 2026 operating profit, Q1 earnings improved or were healthy versus consensus, the share price remains below the 2025 year-end close as of June 10, 2026, and Q1 operating profit is at least KRW 5bn.
From that group, the main Q3 watchlist is Korea Petrochemical, SK Biopharmaceuticals, Samsung Biologics, Krafton, and GKL. The second tier is SK Gas, Dentium, Humedix, Telechips, ST Pharm, and LG H&H.
This is not a buy-now list. The screen identifies candidates where earnings expectations improved but price has not yet followed. For Q3, the required confirmations are flow turn, chart repair, and further estimate support.
1. Why this screen matters now
Korea is not in a broad bull market. The index is being pulled by Samsung Electronics, SK Hynix, defense, shipbuilding, power equipment, and a narrow subset of semiconductor equipment. The average stock feels much weaker. ADR is low, and foreign/institutional buying is concentrated.
In this regime, “cheap” is not enough. A stock can have better numbers and still remain ignored for months.
The purpose of this post is narrow.
| Question | Answer |
|---|---|
| Is the Samsung-Hynix concentration over? | No. Samsung Electronics and SK Hynix remain Korea’s core market axis. |
| Should investors ignore everything else? | No. Q3 is a good time to prepare a quality watchlist with improving numbers and lagging price. |
| Is this a buy-now list? | No. This is a research queue. Flow turn and price repair are required. |
| What matters most? | EPS revisions, Q1 earnings, price lag, real-money flow, and Q2 confirmation. |
2. Data and filters
The source is the Thesis OS local database. Price, flow, and consensus data are as of June 10, 2026.
| Item | Standard |
|---|---|
| Price date | 2026-06-10 |
| Year-end base price | 2025-12-30 close |
| EPS revision comparison | First local consensus observation, mostly 2026-04-14, versus latest FY2026 EPS on 2026-06-10 |
| Earnings metric | Q1 2026 operating profit |
| Minimum profit scale | Q1 OP at least KRW 5bn |
This is conservative, but not perfect. Consensus history is short for some names, and valuation fields are missing for a few smaller companies. Treat the result as a Q3 research queue, not as final recommendations.
3. Candidate screen: numbers improved, price lagged
The screen surfaced 35 companies. Key names include SK Gas, Intops, GC Biopharma, Telechips, SK Biopharmaceuticals, Seers, Korea District Heating, Humedix, Korea Petrochemical, LG H&H, Kakao Pay, Samsung Biologics, Kakao, Korea Gas, Hanssem, Krafton, GKL, Macus, HL Holdings, Clio, Dongwon Industries, Whanin Pharm, HK inno.N, Dentium, Hanwha Ocean, ST Pharm, Lotte Wellfood, and Kumho Petrochemical.
The highest-signal first-pass names are:
| Company | Price | YTD | FY26 EPS revision | Q1 OP | Q1 OPM | Forward P/E | First read |
|---|---|---|---|---|---|---|---|
| SK Gas | 215,500 | -4.2% | +101.8% | KRW 227.7bn | 8.6% | 4.0x | Earnings revised up, price still lagging |
| Telechips | 11,990 | -25.0% | +46.1% | KRW 6.1bn | 9.3% | N/A | Neglected automotive semiconductor name |
| SK Biopharmaceuticals | 86,400 | -30.7% | +23.6% | KRW 89.8bn | 39.4% | 20.0x | High-margin growth stock under pressure |
| Humedix | 26,300 | -34.8% | +18.2% | KRW 8.9bn | 22.0% | N/A | High-margin healthcare laggard |
| Korea Petrochemical | 119,600 | -17.4% | +35.9% | KRW 73.6bn | 8.7% | 7.0x | Chemical turnaround |
| LG H&H | 234,500 | -9.3% | +42.8% | KRW 107.8bn | 6.8% | 22.0x | Consumer turnaround option |
| Samsung Biologics | 1,298,000 | -23.4% | +6.2% | KRW 580.8bn | 46.2% | 31.0x | High quality, price compressed |
| Krafton | 232,000 | -5.7% | +15.8% | KRW 561.6bn | 41.0% | 10.0x | Clean quality-value candidate |
| GKL | 12,070 | -19.4% | +9.6% | KRW 18.1bn | 16.4% | 13.0x | Casino recovery name |
| Dentium | 43,950 | -4.9% | +8.0% | KRW 15.9bn | 22.2% | 6.0x | Valuation attractive |
4. Four buckets
| Bucket | Names | Core logic | Main caution |
|---|---|---|---|
| A. Classic quality | Krafton, Samsung Biologics, SK Biopharmaceuticals | High margin, earnings confirmed, strong business quality | Flow and chart may still be weak |
| B. Turnaround | Korea Petrochemical, LG H&H, Hanssem, Telechips | Earnings expectations improved sharply while price stayed weak | Cycle confirmation needed |
| C. Low-P/E value | SK Gas, Dentium, Dongwon Industries, Korea Gas | Valuation support | Policy, governance, and cycle discounts |
| D. Small/mid-cap laggards | Humedix, Macus, Whanin Pharm, ST Pharm | Stable or improving earnings but low attention | Liquidity and flow may be insufficient |
For Q3, A and B matter most. A asks whether a good company has become cheap enough. B asks whether the turnaround is real. C can stay cheap for too long, and D may need stronger liquidity before price responds.
5. Q3 focus list
A buy-today list and a revisit-in-two-months list are not the same. In Q3, investors will have Q2 previews and second-half guidance. Under that lens, the more important candidates are the ones that look discarded today but still have live numbers.
| Rank | Company | Core evidence | Q3 trigger |
|---|---|---|---|
| 1 | Korea Petrochemical | FY26 EPS +35.9%, P/E 7x, 20D foreign +KRW 2.39bn, program +KRW 1.85bn | Regain KRW 125,000 and flows stay positive |
| 2 | SK Biopharmaceuticals | Q1 OPM 39.4%, FY26 EPS +23.6%, earnings-confirmed growth | Regain KRW 90,000 and institutional selling slows |
| 3 | Samsung Biologics | Q1 OPM 46.2%, 20D foreign +KRW 62.9bn, high-quality drawdown | Regain KRW 1.33-1.35mn |
| 4 | Krafton | Q1 OP KRW 561.6bn, OPM 41.0%, P/E 10x | Institutional selling ends and KRW 240,000 is reclaimed |
| 5 | GKL | Q2 consensus raised, chart repair ahead of peers | Hold KRW 11,800-12,200 or break KRW 12,700 |
Korea Petrochemical is the most interesting two-month candidate. It is too cyclical for a blind entry, but the current price already reflects a lot of disbelief. FY26 EPS has been revised up 35.9%, and forward P/E is 7x. If spread improvement or Q2 earnings confirmation appears in July or August, the re-rating path is open.
SK Biopharmaceuticals does not yet have clean flow. Twenty-day foreign net buying is only KRW 0.23bn, while real-money institutions are negative KRW 8.11bn. But Q1 operating profit of KRW 89.8bn and OPM of 39.4% are strong. If institutional selling stops and the stock regains KRW 90,000, it becomes a growth-stock re-entry candidate.
Samsung Biologics is the cleanest large-cap quality candidate. It is down 23.4% YTD and 20.1% over 60 days, while 20D foreign net buying is +KRW 62.9bn. If the stock regains the KRW 1.33-1.35mn area, foreign buying may start translating into price.
Krafton is hard to buy immediately. Twenty-day real-money institutional flow is -KRW 82.16bn and retail buying is +KRW 38.0bn. But Q1 OP of KRW 561.6bn, OPM of 41.0%, and P/E of 10x are too good to ignore. If institutional selling ends, it can be the first large game-stock recovery candidate.
GKL is currently one of the cleaner candidates, but in two months it may already be the name that moved first. It needs casino/tourism indicators to hold and the KRW 12,000 area to remain support.
6. Deprioritized or wait
| Company | Why not now |
|---|---|
| Hanwha Ocean | 20D foreign -KRW 268.2bn, program -KRW 316.4bn, retail +KRW 337.8bn. Wait for flow turn. |
| Kakao | Foreign and institutions both selling; re-rating structure still weak. |
| Kakao Pay | P/E 50x. Drawdown exists, but valuation safety margin is limited. |
| Seers | Flow can look good, but 60D -47.3% and Q2 estimates cut. Wait for bottom confirmation. |
| LG H&H | EPS revision is good, but real-money and program flow are weak. Need China/cosmetics flow confirmation. |
| Korea Gas / Korea District Heating | Numbers are good, but policy, tariff, and regulation discounts can keep them cheap for a long time. |
7. Execution framework for Q3
| Check | Pass condition | Meaning |
|---|---|---|
| Consensus | No further FY26 EPS or Q2 OP estimate cuts | Numbers remain intact |
| Flow | 20D foreign + real-money institutional flow turns positive | Actual buying power appears |
| Chart | Reclaim 20DMA, approach 60DMA, no new low | Downtrend begins to soften |
| Catalyst | Q2 preview, industry data, company event | Market gets a reason to revisit |
Flow matters most. In this market, better estimates do not move stocks unless money comes in. The key is not headline institutions, but real-money institutions: funds, private funds, pension-type money.
8. Investment view
First, the Samsung-Hynix concentration likely continues. Samsung Electronics and SK Hynix remain the first axis of the Korean market. AI memory, HBM4, relative valuation versus Micron, and foreign-investor playbooks all keep these two names in focus.
Second, Q3 is still the right time to prepare a second-line quality list. Markets periodically rotate from “leaders that already moved” to “stocks with improving numbers that have not moved yet.” This screen identifies that queue.
Third, the task today is to finalize the watchlist, not to buy the entire screen. Put Korea Petrochemical, SK Biopharmaceuticals, Samsung Biologics, Krafton, and GKL in the first focus group. Track SK Gas, Dentium, Humedix, Telechips, and ST Pharm as the second group.
PM summary:
In two months, the important names may not be today’s strongest stocks. They may be the stocks currently ignored despite still-live numbers. On that basis, Korea Petrochemical is the most asymmetric candidate. SK Biopharmaceuticals and Samsung Biologics become immediate research candidates if flows turn. Krafton has excellent numbers, but the institutional selling must stop first.
Evidence Classification
[Fact]
- Source data comes from the Thesis OS local database. Price, flow, and consensus date: 2026-06-10.
- Screen conditions: FY2026 EPS revised up at least 5%, positive Q1 operating profit, Q1 earnings improvement or healthy versus consensus, current price below 2025 year-end close, and Q1 OP above KRW 5bn.
- The screen returns 35 companies.
[Inference]
- This is not a confirmed undervaluation list. It is a list of companies where estimates improved while price has lagged.
- In Q3, even if the Samsung-Hynix concentration continues, some capital may rotate toward quality laggards with live numbers.
- Korea Petrochemical has the largest turnaround asymmetry, while SK Biopharmaceuticals, Samsung Biologics, and Krafton become higher-priority if flows turn.
[Speculation]
- If Korea Petrochemical receives spread improvement or Q2 confirmation in July/August, re-rating could begin.
- SK Biopharmaceuticals and Samsung Biologics could regain quality-growth interest if institutional/foreign flows start moving price.
- Krafton could recover first among game stocks if institutional selling stops.
[Blocked]
- Full analyst-report text and latest detailed consensus breakdown were not re-verified name by name.
- Price and flow are based on the 2026-06-10 local database snapshot. Later moves are not reflected.
- Regulated/policy-sensitive names such as Korea Gas, Korea District Heating, and SK Gas cannot be judged by P/E alone.
Disclaimer: For research and information purposes only. Not investment advice. Names cited are for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision.